BAY-1158061

The endometriosis clinical trial landscape is robust, featuring over 15 companies developing more than 20 potential therapies.

Eirion Therapeutics reports positive Phase 1 results for ET-02, a topical treatment for androgenic alopecia, demonstrating safety and tolerability.

HopeMed's HMI-115, a prolactin inhibitor, demonstrates potential as a first-line treatment for endometriosis-associated pain, according to interim Phase II results.

HMI-115, a new drug for endometriosis, significantly reduces pain and uniquely allows patients to become pregnant during treatment.

Hope Medicine's HMI-115, a first-in-class monoclonal antibody, significantly reduced endometriosis-associated pain in a Phase 2 trial.